Protective immunity against α-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant

Human Gene Therapy

Volumn 16, Issue 3, 2005, Pages 292-298

  Pergolizzi, Robert G ^a   Dragos, Rachel ^a   Ropper, Alexander E ^a   Menez, André ^b   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COBROTOXIN; NICOTINIC RECEPTOR; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; DNA BINDING; GENE DELIVERY SYSTEM; GENE MUTATION; IMMUNIZATION; MORTALITY; MOUSE; NEUROTOXICITY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PROTECTION; PROVOCATION TEST; SNAKE; SNAKEBITE; SURVIVAL RATE;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; COBRA NEUROTOXINS; DNA, COMPLEMENTARY; FEMALE; GENETIC VECTORS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROTEIN CONFORMATION; RECEPTORS, NICOTINIC; SNAKE BITES; VACCINES, DNA;

EID: 16344371197     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.292     Document Type: Article

References (45)

1. ANTIL-DELBEKE, S., GAILLARD, C., TAMIYA, T., CORRINGER, P.J., CHANGEUX, J.P., SERVENT, D., and MENEZ, A. (2000). Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor. J. Biol. Chem. 275, 29594-29601.
2. ANTIL, S., SERVENT, D., and MENEZ, A. (1999). Variability among the sites by which curaremimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the functional residues of alpha-cobratoxin. J. Biol. Chem. 274, 34851-34858.
3. BAIG, J., LEVY, D.B., MCKAY, P.F., SCHMITZ, J.E., SANTRA, S., SUBBRAMANIAN, R.A., KURODA, M.J., LIFTON, M.A., GORGONE, D.A., WYATT, L.S., MOSS, B., HUANG, Y., CHAKRABARTI, B.K., XU, L., KONG, W.P., YANG, Z.Y., MASCOLA, J.R., NABEL, G.J., CARVILLE, A., LACKNER, A.A., VEAZEY, R.S., and LETVIN, N.L. (2002). Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J. Virol. 76, 11484-11490.
4. BRAMSON, J.L., and WAN, Y.H. (2002). The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert. Opin. Biol. Ther. 2, 75-85.
5. BUGE, S.L., RICHARDSON, E., ALIPANAH, S., MARKHAM, P., CHENG, S., KALYAN, N., MILLER, C.J., LUBECK, M., UDEM, S., ELDRIDGE, J., and ROBERT-GUROFF, M. (1997). An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71, 8531-8541.
6. CHENG, A.C., and WINKEL, K. (2001a). Call for global snake-bite control and procurement funding. Lancet 357, 1132.
7. CHENG, A.C., and WINKEL, K.D. (2001b). Snakebite and antivenoms in the Asia-Pacific: wokabaut wantaim, raka hebou ("walking together"). Med. J. Aust. 175, 648-651.
8. CHENG, A.C., and WINKEL, K.D. (2004). Antivenom efficacy, safety and availability: measuring smoke. Med. J. Aust. 180, 5-6.
9. CHENG, S.M., LEE, S.G., RONCHETTI-BLUME, M., VIRK, K.P., MIZUTANI, S., EICHBERG, J.W., DAVIS, A., HUNG, P.P., HIRSCH, V.M., and CHANOCK, R.M. (1992). Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J. Virol. 66, 6721-6727.
10. CHIPPAUX, J.P. (1998). Snake-bites: appraisal of the global situation. Bull. World Health Organ. 76, 515-524.
11. CHIRMULE, N., PROPERT, K., MAGOSIN, S., QIAN, Y., QIAN, R., and WILSON, J. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-1583.
12. CRYSTAL, R.G., HARVEY, B.G., WISNIVESKY, J.P., O'DONOGHUE, K.A., CHU, K.W., MARONI, J., MUSCAT, J.C., PIPPO, A.L., WRIGHT, C.E., KANER, R.J., LEOPOLD, P.L., KESSLER, P.D., RASMUSSEN, H.S., ROSENGART, T.K., and HOLLMANN, C. (2002). Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13, 65-100.
13. ELAHI, S.M., SHEN, S.H., TALBOT, B.C., MASSIE, B., HARPIN, S., and ELAZHARY, Y. (1999). Induction of humoral and cellular immune responses against the nucleocapsid of bovine viral diarrhea virus by an adenovirus vector with an inducible promoter. Virology 261, 1-7.
14. FARINA, S.F., GAO, G.P., XIANG, Z.Q., RUX, J.J., BURNETT, R.M., ALVIRA, M.R., MARSH, J., ERTL, H.C., and WILSON, J.M. (2001). Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75, 11603-11613.
15. FLANAGAN, B., PRINGLE, C.R., and LEPPARD, K.N. (1997). A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. J. Gen. Virol. 78, 991-997.
16. FOOKS, A.R., SCHADECK, E., LIEBERT, U.G., DOWSETT, A.B., RIMA, B.K., STEWARD, M., STEPHENSON, J.R., and WILKINSON, G.W. (1995). High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: Induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210, 456-465.
17. FRUCHART-GAILLARD, C., GILQUIN, B., ANTIL-DELBEKE, S., LE NOVERE, N., TAMIYA, T., CORRINGER, P.J., CHANGEUX, J.P., MENEZ, A., and SERVENT, D. (2002). Experimentally based model of a complex between a snake toxin and the alpha 7 nicotinic receptor. Proc. Natl. Acad. Sci. U.S.A. 99, 3216-3221.
18. GEUTSKENS, S.B., VAN DER EB, M.M., PLOMP, A.C., JONGES, L.E., CRAMER, S.J., ENSINK, N.G., KUPPEN, P.J., and HOEBEN, R.C. (2000). Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther. 7, 1410-1416.
19. HACKETT, N.R., and CRYSTAL, R.G. (2000). Adenovirus vectors for gene therapy. In Gene Therapy: Therapeutic Mechanisms and Strategies. D. Lasic and N.S.Templeton, eds. (Marcel Dekker, New York), pp. 17-40.
20. HARVEY, B.G., HACKETT, N.R., ELY, S., and CRYSTAL, R.G. (2001). Host responses and persistence of vector genome following intrabronchial administration of an E1 - E3 - adenovirus gene transfer vector to normal individuals. Mol. Ther. 3, 206-215.
21. HARVEY, B.G., MARONI, J., O'DONOGHUE, K.A., CHU, K.W., MUSCAT, J.C., PIPPO, A.L., WRIGHT, C.E., HOLLMANN, C., WISNIVESKY, J.P., KESSLER, P.D., RASMUSSEN, H.S., ROSENGART, T.K., and CRYSTAL, R.G. (2002). Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 13, 15-63.
22. - adenovirus gene transfer vector. Hum. Gene Ther. 10, 2823-2837.
23. HE, Z., WLAZLO, A.P., KOWALCZYK, D.W., CHENG, J., XIANG, Z.Q., GILES-DAVIS, W., and ERTL, H.C. (2000). Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270, 146-161.
24. HERSH, J., CRYSTAL, R.G., and BEWIG, B. (1995). Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther. 2, 124-131.
25. LIU, F., SONG, Y., and LIU, D. (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258-1266.
26. LUBECK, M.D., DAVIS, A.R., CHENGALVALA, M., NATUK, R.J., MORIN, J.E., MOLNAR-KIMBER, K., MASON, B.B., BHAT, B.M., MIZUTANI, S., and HUNG, P.P. (1989). Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. U.S.A. 86, 6763-6767.
27. MAKIMURA, M., MIYAKE, S., AKINO, N., TAKAMORI, K., MATSUURA, Y., MIYAMURA, T., and SAITO, I. (1996). Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 14, 28-36.
28. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
29. MOLINIER-FRENKEL, V., LENGAGNE, R., GADEN, F., HONG, S.S., CHOPPIN, J., GAHERY-SEGARD, H., BOULANGER, P., and GUILLET, J.G. (2002). Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76, 127-135.
30. MORAN, N.F., NEWMAN, W.J., THEAKSTON, R.D., WARRELL, D.A., and WILKINSON, D. (1998). High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom. Trans. R. Soc. Trop. Med. Hyg. 92, 69-70.
31. NATUK, R.J., CHANDA, P.K., LUBECK, M.D., DAVIS, A.R., WILHELM, J., HJORTH, R., WADE, M.S., BHAT, B.M., MIZUTANI, S., and LEE, S. (1992). Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc. Natl. Acad. Sci. U.S.A. 89, 7777-7781.
32. PREVEC, L., CAMPBELL, J.B., CHRISTIE, B.S., BELBECK, L., and GRAHAM, F.L. (1990). A recombinant human adenovirus vaccine against rabies. J. Infect. Dis. 161, 27-30.
33. ROSENFELD, M.A., SIEGFRIED, W., YOSHIMURA, K., YONEYAMA, K., FUKAYAMA, M., STIER, L.E., PAAKKO, P.K., GILARDI, P., STRATFORD-PERRICAUDET, L.D., and PERRICAUDET, M. (1991). Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252, 431-434.
34. ROSENFELD, M.A., YOSHIMURA, K., TRAPNELL, B.C., YONEYAMA, K., ROSENTHAL, E.R., DALEMANS, W., FUKAYAMA, M., BARGON, J., STIER, L.E., and STRATFORD-PERRICAUDET, L. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
35. SHIVER, J.W., FU, T.M., CHEN, L., CASIMIRO, D.R., DAVIES, M.E., EVANS, R.K., ZHANG, Z.Q., SIMON, A.J., TRIGONA, W.L., DUBEY, S.A., HUANG, L., HARRIS, V.A., LONG, R.S., LIANG, X., HANDT, L., SCHLEIF, W.A., ZHU, L., FREED, D.C., PERSAUD, N.V., GUAN, L., PUNT, K.S., TANG, A., CHEN, M., WILSON, K.A., COLLINS, K.B., HEIDECKER, G.J., FERNANDEZ, V.R., PERRY, H.C., JOYCE, J.G., GRIMM, K.M., COOK, J.C., KELLER, P.M., KRESOCK, D.S., MACH, H., TROUTMAN, R.D., ISOPI, L.A., WILLIAMS, D.M., XU, Z., BOHANNON, K.E., VOLKIN, D.B., MONTEFIORI, D.C., MIURA, A., KRIVULKA, G.R., LIFTON, M.A., KURODA, M.J., SCHMITZ, J.E., LETVIN, N.L., CAULFIELD, M.J., BETT, A.J., YOUIL, R., KASLOW, D.C., and EMINI, E.A. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
36. SOIFFER, R., HODI, F.S., HALUSKA, F., JUNG, K., GILLESSEN, S., SINGER, S., TANABE, K., DUDA, R., MENTZER, S., JAKLITSCH, M., BUENO, R., CLIFT, S., HARDY, S., NEUBERG, D., MULLIGAN, R., WEBB, I., MIHM, M., and DRANOFF, G. (2003). Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21, 3343-3350.
37. SUNDELL, I.B., RANBY, M., ZUZEL, M., ROBINSON, K.A., and THEAKSTON, R.D. (2003). In vitro procoagulant and anticoagulant properties of Naja naja naja venom. Toxicon 42, 239-247.
38. THEAKSTON, R.D., and KAMIGUTI, A.S. (1998). Viper envenoming: evaluation of treatment by restoration of hemostasis and venom clearance. J. Venom. Anim. Toxins 4, 94-111.
39. THEAKSTON, R.D., WARRELL, D.A., and GRIFFITHS, E. (2003). Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 41, 541-557.
40. VINNER, L., WEE, E.G., PATEL, S., CORBET, S., GAO, G.P., NIELSEN, C., WILSON, J.M., ERTL, H.C., HANKE, T., and FOMSGAARD, A. (2003). Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J. Gen. Virol. 84, 203-213.
41. WORGALL, S., BUSCH, A., RIVARA, M., BONNYAY, D., LEOPOLD, P.L., MERRITT, R., HACKETT, N.R., ROVELINK, P.W., BRUDER, J.T., WICKHAM, T.J., KOVESDI, I., and CRYSTAL, R.G. (2004). Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J. Virol. 78, 2572-2580.
42. XIANG, Z., GAO, G., REYES-SANDOVAL, A., COHEN, C.J., LI, Y., BERGELSON, J.M., WILSON, J.M., and ERTL, H.C. (2002). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76, 2667-2675.
43. ZAKHARTCHOUK, A.N., REDDY, P.S., BAXI, M., BACA-ESTRADA, M.E., MEHTALI, M., BABIUK, L.A., and TIKOO, S.K. (1998). Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Virology 250, 220-229.
44. WUSTER, W. (1996). Taxonomic changes and toxinology: Systematic revisions of the Asiatic cobras (Naja naja species complex). Toxicon 34, 399-406.
45. ZHANG, Y., CHIRMULE, N., GAO, G.P., QIAN, R., CROYLE, M., JOSHI, B., TAZELAAR, J., and WILSON, J.M. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3, 697-707.